PS
AVDL

Principal Securities’s Avadel Pharmaceuticals AVDL Stock Holding History

Principal Securities’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9
Closed -$79 – 3692
2025
Q1 		$95 Hold
9
– – ﹤0.01% 3510
2024
Q4 		$95 Hold
9
– – ﹤0.01% 3505
2024
Q3 		$118 Buy
+9
New +$137 ﹤0.01% 3405

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Securities's AVDL Position: Q2 2025 in Review

Principal Securities sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 9 shares — an estimated $79 sold.

Principal Securities first reported a position in AVDL in Q3 2024 and held it in 3 quarters. The position peaked at $118 in Q3 2024. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Principal Securities reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 9 Avadel Pharmaceuticals shares in Q2 2025, an estimated $79.
  • Principal Securities first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Principal Securities's Avadel Pharmaceuticals position peaked at $118 in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.